Summary

Eligibility
for people ages 5-17 (full criteria)
Location
at UCSD
Dates
study started
study ends around

Description

Summary

The purpose of this study is to evaluate the long-term safety and tolerability of cariprazine in the treatment of pediatric participants with schizophrenia, bipolar I disorder, or autism spectrum disorder (ASD) and to establish the benefit-risk profile of long-term treatment in this population.

Official Title

A 52-Week, Multicenter, Open-Label, Flexible-dose Study to Evaluate the Long-term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Subjects With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder

Keywords

Schizophrenia, Bipolar I Disorder, Autism Spectrum Disorder (ASD), Cariprazine, Autistic Disorder, Autism Spectrum Disorder, Pervasive Child Development Disorders, Cariprazine Flexible Dose

Eligibility

Locations

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
AbbVie
Links
Related Info
ID
NCT04578756
Phase
Phase 3 research study
Study Type
Interventional
Participants
About 310 people participating
Last Updated